Reata Pharmaceuticals Inc. [NASDAQ: RETA] loss -33.16% on the last trading session, reaching $104.41 price per share at the time. The company report on August 10, 2020 that Reata Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs.
PRE-NDA (NEW DRUG APPLICATION) MEETING GRANTED FOR BARDOXOLONE.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
REGULATORY UPDATE ON OMAVELOXOLONE.
Reata Pharmaceuticals Inc. represents 33.22 million in outstanding shares, while the company has a total market value of $3.37 billion with the latest information. RETA stock price has been found in the range of $102.22 to $125.00.
If compared to the average trading volume of 337.99K shares, RETA reached a trading volume of 4037287 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Reata Pharmaceuticals Inc. [RETA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RETA shares is $269.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RETA stock is a recommendation set at 1.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stifel have made an estimate for Reata Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 10, 2020. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on June 17, 2020, representing the official price target for Reata Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Reata Pharmaceuticals Inc. is set at 9.75, with the Price to Sales ratio for RETA stock in the period of the last 12 months amounting to 167.89. The Price to Book ratio for the last quarter was 15.18, with the Price to Cash per share for the same quarter was set at 19.32.
Trading performance analysis for RETA stock
Reata Pharmaceuticals Inc. [RETA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -30.06. With this latest performance, RETA shares dropped by -32.38% in over the last four-week period, additionally sinking by -55.37% over the last 6 months – not to mention a rise of 27.94% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RETA stock in for the last two-week period is set at 20.65, with the RSI for the last a single of trading hit 15.86, and the three-weeks RSI is set at 27.86 for Reata Pharmaceuticals Inc. [RETA]. The present Moving Average for the last 50 days of trading for this stock 153.39, while it was recorded at 142.55 for the last single week of trading, and 177.30 for the last 200 days.
Reata Pharmaceuticals Inc. [RETA]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Reata Pharmaceuticals Inc. [RETA] shares currently have an operating margin of -1075.61. Reata Pharmaceuticals Inc.’s Net Margin is presently recorded at -1094.28.
Return on Total Capital for RETA is now -77.80, given the latest momentum, and Return on Invested Capital for the company is -100.04. Return on Equity for this stock declined to -213.35, with Return on Assets sitting at -56.47. When it comes to the capital structure of this company, Reata Pharmaceuticals Inc. [RETA] has a Total Debt to Total Equity ratio set at 148.73. Additionally, RETA Total Debt to Total Capital is recorded at 59.80, with Total Debt to Total Assets ending up at 55.98. Long-Term Debt to Equity for the company is recorded at 89.10, with the Long-Term Debt to Total Capital now at 35.82.
Reflecting on the efficiency of the workforce at the company, Reata Pharmaceuticals Inc. [RETA] managed to generate an average of -$1,318,955 per employee.Reata Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.20 and a Current Ratio set at 3.20.
Reata Pharmaceuticals Inc. [RETA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Reata Pharmaceuticals Inc. posted -1.14/share EPS, while the average EPS was predicted by analysts to be reported at -1.12/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -1.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RETA.
An analysis of insider ownership at Reata Pharmaceuticals Inc. [RETA]
There are presently around $2,370 million, or 80.80% of RETA stock, in the hands of institutional investors. The top three institutional holders of RETA stocks are: CPMG INC with ownership of 3,063,567, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; WELLINGTON MANAGEMENT GROUP LLP, holding 3,020,924 shares of the stock with an approximate value of $315.42 million in RETA stocks shares; and VANGUARD GROUP INC, currently with $233.85 million in RETA stock with ownership of nearly 3.362% of the company’s market capitalization.
Positions in Reata Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 115 institutional holders increased their position in Reata Pharmaceuticals Inc. [NASDAQ:RETA] by around 2,794,840 shares. Additionally, 104 investors decreased positions by around 2,333,520 shares, while 37 investors held positions by with 17,568,513 shares. The mentioned changes placed institutional holdings at 22,696,873 shares, according to the latest SEC report filing. RETA stock had 39 new institutional investments in for a total of 562,407 shares, while 37 institutional investors sold positions of 551,662 shares during the same period.